emivirine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Emivirine (MKC-442) is a failed experimental agent for the treatment of HIV. It is a non-nucleoside reverse transcriptase inhibitor. While emivirine showed promising antiviral activity in vitro, it failed to show sufficient efficacy in human trials. However it is still notable as an early proof of concept, which led to the discovery of a number of related antiviral drugs.   Wikipedia

Chemistry

  • SMILES: CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O
  • InChIKey: MLILORUFDVLTSP-UHFFFAOYSA-N
  • Mol. Mass: 302.37
  • ALogP: 2.24
  • ChEMBL Molecule:
    emivirine  
More Chemistry

Pharmacology

Alternative names

1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1h,3h)-dione | 2,4(1h,3h)-pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)- | 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil | 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil | 6-benzyl-1-ethoxymethyl-5-isopropyluracil | coactinon | emivirine | mkc 442 | mkc-442

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

HIV Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue